Quick Answer
ABBOTT LABORATORIES reported Total Revenue of $44.33 billion for fiscal year 2025.
ABBOTT LABORATORIES — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $44.33B +5.7% |
$41.95B +4.6% |
$40.11B -8.1% |
$43.65B +1.3% |
$43.08B +24.5% |
$34.61B +8.5% |
| Revenue (ASC 606) | $44.33B +5.7% |
$41.95B +4.6% |
$40.11B -8.1% |
$43.65B +1.3% |
$43.08B +24.5% |
$34.61B +8.5% |
| Net Income | $6.52B -51.3% |
$13.40B +134.2% |
$5.72B -17.5% |
$6.93B -2.0% |
$7.07B +57.3% |
$4.50B +21.9% |
| Diluted EPS | $3.72 -51.3% |
$7.64 +134.4% |
$3.26 -16.6% |
$3.91 -0.8% |
$3.94 +57.6% |
$2.50 +21.4% |
| Total Assets | $86.71B +6.5% |
$81.41B +11.2% |
$73.21B -1.6% |
$74.44B -1.0% |
$75.20B +3.6% |
$72.55B +6.9% |
| Cash and Equivalents | $8.52B +11.9% |
$7.62B +10.4% |
$6.90B -30.2% |
$9.88B +0.8% |
$9.80B +43.3% |
$6.84B +77.2% |
| Long-Term Debt | $9.90B -21.6% |
$12.62B -7.2% |
$13.60B -6.4% |
$14.52B -16.0% |
$17.30B -6.6% |
$18.53B +11.2% |
| Stockholders Equity | $52.13B +9.4% |
$47.66B +23.5% |
$38.60B +5.2% |
$36.69B +2.5% |
$35.80B +9.2% |
$32.78B +5.5% |
| R&D Expense | $2.94B +3.4% |
$2.84B +3.8% |
$2.74B -5.1% |
$2.89B +5.3% |
$2.74B +13.3% |
$2.42B -0.8% |
| Operating Income | $8.05B +18.0% |
$6.83B +5.4% |
$6.48B -22.5% |
$8.36B -0.7% |
$8.43B +57.3% |
$5.36B +18.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.37B | +6.9% | +2.0% |
| Revenue (ASC 606) | September 30, 2025 | $11.37B | +6.9% | +2.0% |
| Net Income | September 30, 2025 | $1.64B | -0.1% | -7.6% |
| Diluted EPS | September 30, 2025 | $0.94 | +0.0% | -6.9% |
| Total Assets | September 30, 2025 | $84.18B | +13.2% | +0.2% |
| Cash and Equivalents | September 30, 2025 | $7.51B | -0.6% | +8.1% |
| Long-Term Debt | September 30, 2025 | $11.60B | -9.6% | -10.3% |
| Stockholders Equity | September 30, 2025 | $50.95B | +28.0% | +0.8% |
| R&D Expense | September 30, 2025 | $766.00M | +7.4% | +5.7% |
| Operating Income | September 30, 2025 | $2.06B | +10.7% | +0.2% |
- ABBOTT LABORATORIES reported Total Revenue of $44.33 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +5.7% in Total Revenue compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Revenue (ASC 606) of $44.33 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +5.7% in Revenue (ASC 606) compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Net Income of $6.52 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed a decrease of -51.3% in Net Income compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Diluted EPS of $3.72 per share for fiscal year 2025.
- ABBOTT LABORATORIES showed a decrease of -51.3% in Diluted EPS compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Total Assets of $86.71 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +6.5% in Total Assets compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Cash and Equivalents of $8.52 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +11.9% in Cash and Equivalents compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Long-Term Debt of $9.90 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed a decrease of -21.6% in Long-Term Debt compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Stockholders Equity of $52.13 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +9.4% in Stockholders Equity compared to the prior fiscal year.
- ABBOTT LABORATORIES reported R&D Expense of $2.94 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +3.4% in R&D Expense compared to the prior fiscal year.
- ABBOTT LABORATORIES reported Operating Income of $8.05 billion for fiscal year 2025.
- ABBOTT LABORATORIES showed an increase of +18.0% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: